Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
918524-63-7CN1CCN(c2ccc(B3OC(C)(C)C(C)(C)O3)cn2)CC1KVQXFNGVIIPCSX-UHFFFAOYSA-NSicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Danger
H302 (16.7%): Harmful if swallowed [Warning Acute toxicity, oral]
P260, P261, P264, P264+P265, P270, P271, P280, P301+P317, P301+P330+P331, P302+P352, P302+P361+P354, P304+P340, P305+P351+P338, P305+P354+P338, P316, P317, P319, P321, P330, P332+P317, P337+P317, P362+P364, P363, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 6 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Verwenden1-Methyl-4-[5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)pyridin-2-yl]piperazine is used to prepare yrazolopyridine and indazoles as histone lysine methyltransferase EZH2 inhibitors. It is also used to synthesize tetrahydropyrido pyrazines as anaplastic lymphoma kinase inhibitors.
918524-63-7DTXSID50377794